Search

According to frailty scoring, 72 patients (67.9%) were frail, whilst 34 patients (32.1%) were non-frail. Keywords: frailty; isatuximab; myeloma; pomalidomide; real-world EN frailty isatuximab myeloma pomalidomide real-world 162 167 6 03/30/23 20230401 NES 230401 Multiple myeloma (MM) is primarily a disease of the elderly with 43% of the UK's newly diagnosed (NDMM) patients aged 75 years and over.[1] The highest incidence rates in the UK in both males and females occur in those aged 85-89 years.[1] A structured frailty assessment is needed in elderly myeloma patients in order to individualise treatment decisions.[2] In the relapsed/refractory (RRMM) setting, frailty-based approach to therapy is equally required to devise patient-centred treatment plans, which can reduce the risk of under-treating fit patients and the risk of over-treating frail patients. Baseline patient, disease and treatment characteristics of the different frailty subgroups are fully presented in Table 1. 1 TABLE Baseline patient, disease and treatment characteristics according to frailty subgroups. It is important to bear in mind that comparing the number of episodes between frailty subgroups is limited by the significant difference in cohort size between those subgroups (frail: 72 patients vs. non-frail: 34 patients). [Extracted from the article]

The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience Keywords: SARS-CoV-2; COVID-19; bone marrow transplantation; post transplant cyclophosphamide; conditioning EN SARS-CoV-2 COVID-19 bone marrow transplantation post transplant cyclophosphamide conditioning e67 e70 4 07/20/20 20200715 NES 200715 Coronavirus disease 2019 (COVID-19) is caused by the novel SARS-CoV-2 virus and has been declared a pandemic on the 9th of March by the WHO. Five out of seven (71%) were in complete remission from underlying disease, and two of them (29%) had relapsed acute myeloid leukaemia (AML) with bone marrow chimerism 79% and 27% donor at COVID-19 diagnosis. [Extracted from the article]

Keywords: DPACE; DTPACE; efficacy; myeloma; survival; VRDPACE; VTDPACE EN DPACE DTPACE efficacy myeloma survival VRDPACE VTDPACE 231 233 3 07/24/20 20200801 NES 200801 The use of dexamethasone plus thalidomide in combination with a continuous infusion of cisplatin, doxorubicin, cyclophosphamide and etoposide (DTPACE) was first described in relapsed myeloma (MM) and showed effectiveness as induction therapy before autologous stem cell transplant (ASCT).1 The addition of bortezomib to DTPACE (VTDPACE) led to improved outcomes.2,3 Historical indications for DPACE-based therapies include salvage treatment of aggressive MM, plasma cell leukaemia and initial presentation with extra-medullary disease. Baseline patient, disease and treatment characteristics were collected from the local chemotherapy database and patient records between 2009 and 2017. The majority of patients who received >2 lines of therapy had received a prior ASCT (15/17:88.2%) and only a small group (3/17:17.6%) consolidated DPACE with a further ASCT (2 SP nd sp ASCT in all 3 patients). [Extracted from the article]

Introduction. Acute urinary retention in a child is rare. Haematocolpos can cause a mechanical obstruction, resulting in acute urinary retention. Case Report. A 12-year-old girl presented to the surgical department with a one-day history of acute urinary retention and suprapubic tenderness. She had not started menses but had described period-like pains every month for the past six months. On examination, she had a palpable bladder with over 500mls of residual urine and a bluish-grey bulge posterior to her urethral meatus. An US scan showed a large mass posterior to her bladder resembling a haematocolpos, and this was confirmed with an MRI scan. She was catheterised and eventually underwent a hymenectomy using a cruciate incision. She made a good recovery postoperatively. Conclusion. In the case of a peripubertal female presenting with acute urinary retention, haematocolpos should be considered as a diagnosis. [ABSTRACT FROM AUTHOR]